A
Ana Chauca-Diaz
Researcher at Anschutz Medical Campus
Publications - 5
Citations - 187
Ana Chauca-Diaz is an academic researcher from Anschutz Medical Campus. The author has contributed to research in topics: Cancer & Bladder cancer. The author has an hindex of 4, co-authored 5 publications receiving 90 citations. Previous affiliations of Ana Chauca-Diaz include University of Colorado Boulder.
Papers
More filters
Journal ArticleDOI
Targeting DDR2 enhances tumor response to anti–PD-1 immunotherapy
Megan M. Tu,Francis Y. Lee,Robert T. Jones,Abigail K. Kimball,Elizabeth Saravia,Robert F. Graziano,Brianne M. Coleman,Krista Menard,Jun Yan,Erin Michaud,Han Chang,Hany A. Abdel-Hafiz,Andrii I. Rozhok,Jason E. Duex,Neeraj Agarwal,Ana Chauca-Diaz,Linda K. Johnson,Terry L. Ng,John C. Cambier,Eric T. Clambey,James C. Costello,Alan J. Korman,Dan Theodorescu +22 more
TL;DR: This work shows that DDR2 depletion increases sensitivity to anti–PD-1 treatment compared to monotherapy, and provides strong scientific rationale for targeting DDR2 in combination with PD-1 inhibitors.
Journal ArticleDOI
Inhibition of the CCL2 receptor, CCR2, enhances tumor response to immune checkpoint therapy.
Megan M. Tu,Hany A Abdel-Hafiz,Robert T. Jones,Annie Jean,Katelyn J Hoff,Jason E. Duex,Ana Chauca-Diaz,James C. Costello,Garrett M. Dancik,Beth A. Jirón Tamburini,Bogdan Czerniak,Jonathan Kaye,Dan Theodorescu +12 more
TL;DR: It is shown across multiple murine tumor and metastasis models that CCR2 antagonism in combination with anti- PD-1 therapy leads to sensitization and enhanced tumor response over anti-PD-1 monotherapy and that enhanced treatment response correlates with enhanced CD8 + T cell recruitment and activation and a concomitant decrease in CD4 + regulatory T cell.
Journal ArticleDOI
Androgen Receptor Regulates CD44 Expression in Bladder Cancer.
Joseph L. Sottnik,Lauren A. Vanderlinden,Molishree Joshi,Ana Chauca-Diaz,Charles Owens,Donna E. Hansel,Colin Sempeck,Debashis Ghosh,Dan Theodorescu +8 more
TL;DR: The role of the androgen receptor (AR) in the development of both experimental and human bladder cancer is less clear, with literature indicating that more advanced stage and grade disease are associated with reduced AR expression.
Journal ArticleDOI
Nuclear CD24 Drives Tumor Growth and Is Predictive of Poor Patient Prognosis.
Jason E. Duex,Charles Owens,Ana Chauca-Diaz,Garrett M. Dancik,Lauren A. Vanderlinden,Debashis Ghosh,Mariah Z. Leivo,Donna E. Hansel,Dan Theodorescu +8 more
TL;DR: A novel and functionally important intracellular location of CD24 is defined; it is explained why surCD24- cells can remain aggressive, and the need to consider nucCD24 in both fundamental research and therapeutic development is highlighted.
Journal ArticleDOI
Elucidating the role of Agl in bladder carcinogenesis by generation and characterization of genetically engineered mice
Joseph L. Sottnik,Vandana Mallaredy,Ana Chauca-Diaz,Carolyn Ritterson Lew,Charles Owens,Garrett M. Dancik,Serena Pagliarani,Sabrina Lucchiari,Maurizio Moggio,Michela Ripolone,Giacomo P. Comi,Henry F. Frierson,David E. Clouthier,Dan Theodorescu +13 more
TL;DR: The role of AGL loss in promoting carcinogenesis is supported and a rationale for evaluating Agl expression levels, or Agl Loss gene signature scores, in normal urothelium of populations at risk of BC development such as older male smokers is provided.